305 completed, 50 unknown, 35 terminated, 31 recruiting. 146 Phase 2, 120 Phase 3, 89 Phase 4, 59 Phase 1, 25 Not applicable.
Follow aflibercept: new trials by email Literature Review of aflibercept trials Research Report on aflibercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial aflibercept 8 mg - Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-12-24 | 2026-02-05 |
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study Aflibercept Injection, Ahmed Tube Surgery - Glaucoma | Phase 2 | Not yet recruiting | University of Miami | 100 | 2026-12-01 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration - Neovascular Age Related Macular Degeneration(nAMD) | Phase 2 | Not yet recruiting | Everest Medicines (China) Co.,Ltd. | 244 | 2026-11-01 | 2026-11-05 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02) OLN324, Aflibercept - Diabetic Macular Edema (DME) | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 450 | 2026-10-15 | 2026-09-25 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03) OLN324, Aflibercept - Diabetic Macular Edema (DME) | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 450 | 2026-10-15 | 2026-09-25 |
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04) OLN324, Aflibercept - Wet Age Related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 500 | 2026-10-15 | 2026-09-11 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1104 | 2026-09-25 | 2026-11-03 |
| A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | 4D Molecular Therapeutics | 514 | 2026-09-18 | 2026-11-05 |
| A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema SB15 PFS - Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO | Phase 2 | Completed | Samsung Bioepis Co., Ltd. | 33 | 2026-09-07 | 2026-10-15 |
| Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME Aflibercept 8mg - nAMD, DME | Not yet recruiting | Grupo de Estudos da Retina | 100 | 2026-09-01 | 2026-08-12 | |
| Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration JWK001, Aflibercept (2.0 mg) - Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Phase 2 | Recruiting | West China Hospital | 50 | 2026-08-31 | 2026-08-20 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-08-27 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO Tabirafusp tedromer, Aflibercept (2.0 mg) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Kodiak Sciences Inc | 910 | 2026-08-03 | 2026-11-03 |
| Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients Aflibercept 8mg - Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD | Early Phase 1 | Not yet recruiting | Tianjin Medical University Eye Hospital | 49 | 2026-07-25 | 2026-07-27 |
| A Study to Compare GNR-139 and Eylea® in Patients With nAMD aflibercept, Eylea - nAMD | Phase 3 | Recruiting | AO GENERIUM | 180 | 2026-07-22 | 2026-09-30 |
| Safety and Efficacy of AIV007 Periocular Injection in Patients With Neovascular Age-Related Macular Degeneration AIV007, EYLEA® (aflibercept) Injection 2 mg (0.05mL) - Neovascular (Wet) Age-Related Macular Degeneration | Phase 2 | Recruiting | AiViva BioPharma, Inc. | 35 | 2026-07-01 | 2026-11-04 |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration ABP 938 8 mg, Aflibercept (US) 8 mg - Neovascular Age-related Macular Degeneration, nAMD | Phase 3 | Recruiting | Amgen | 304 | 2026-05-27 | 2026-10-14 |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
| Home Monitoring in eAMD Treatment Aflibercept 8mg - Exudative Age-Related Macular Degeneration | Not yet recruiting | Association for Innovation and Biomedical Research on Light and Image | 80 | 2026-05-01 | 2026-05-06 | |
| Real-World Incidence of Intraocular Inflammation Following Intravitreal Treatment With Aflibercept 8 mg Aflibercept (Eylea) - Intraocular Inflammation, Intravitreal Injections | Completed | Copenhagen University Hospital, Rigshospitalet | 3690 | 2026-04-20 | 2026-09-30 |
Showing 20 of 487. Sign in to see all of them.
Macular Degeneration (99) · Diabetic Retinopathy (45) · Macular Edema (42) · Retinal Vein Occlusion (34) · Wet Macular Degeneration (27) · Colorectal Neoplasms (25) · Choroidal Neovascularization (22) · Retinal Diseases (22) · Eye Diseases (18) · Vision Disorders (16) · Neoplasm Metastasis (15) · Diabetes Mellitus (14) · Retinal Degeneration (14) · Neoplasms (13) · Polypoidal Choroidal Vasculopathy (10)
Bayer (60) · Regeneron Pharmaceuticals (30) · Sanofi (23) · National Cancer Institute (NCI) (20) · Novartis Pharmaceuticals (20) · Hoffmann-La Roche (7) · Kodiak Sciences Inc (7) · Clearside Biomedical, Inc. (6) · EyePoint Pharmaceuticals, Inc. (6) · 4D Molecular Therapeutics (4) · Alcon Research (4) · Jaeb Center for Health Research (4) · Ocular Therapeutix, Inc. (4) · Ophthotech Corporation (4) · Unity Health Toronto (4)
United States (230) · Germany (62) · France (59) · Canada (56) · Italy (55) · Japan (54) · Spain (52) · Hungary (49) · South Korea (45) · United Kingdom (43) · Czechia (41) · China (39) · Australia (36) · Poland (36) · Israel (34)
Pablo Velazquez-Martin, MD (6) · Avner Ingerman, MD (3) · Adam Turpcu, PhD (2) · Ahmad Tarhini (2) · Byung Jhip Ha (2) · Dennis M Marcus, MD (2)
PMID 32374423, PMID 39207600, PMID 19949018, PMID 20028764, PMID 22002018, PMID 23084240, PMID 25012934, PMID 25439429, PMID 25677668, PMID 27847634, PMID 28006063, PMID 29051325, PMID 29785301, PMID 30957581, PMID 30986442, PMID 31826853, PMID 33207259, PMID 34968756, PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36265076, PMID 36897413, PMID 37185961, PMID 37294433, PMID 37535382, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38461841, PMID 38758639, PMID 38852921, PMID 39033924, PMID 40668667, PMID 41534798, PMID 41712218, PMID 42287526, PMID 42753135, PMID 42771326, PMID 11642370, PMID 12750101, PMID 16141858, PMID 16234465, PMID 16483659, PMID 16523231, PMID 16581423, PMID 16787141, PMID 16935211
2014 (9), 2019 (9), 2018 (7), 2017 (5), N01CM62209 (5), 2023 (3), N01CM62201 (2), N01CM62203 (2), P30CA016672 (2), P30CA033572 (2), 2009 (1), 2015 (1), 2016 (1), 2025 (1), N01CM00038 (1)